Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Frances R. Balkwill, Jonathan S. Berek et al.|Nature reviews. Cancer|2011Cited by 1.5k
153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)JC Goh, Michael Millward, Jermaine Coward et al.|Annals of Oncology|2021Cited by 3